Brief: Compass Therapeutics Announces First Patient Dosed In The Phase 1B Ctx-471 Combination Trial With Keytruda® (Pembrolizumab)
01/12/2022 13:34
Dec 1 (Reuters) - Compass Therapeutics Inc. CMPX.O :
* COMPASS THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN THE
PHASE
1B CTX-471 COMBINATION TRIAL WITH KEYTRUDA® (PEMBROLIZUMAB)
Source text for Eikon: ID:nGNX246005
Further company coverage: CMPX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Compass Therapeutics
See all newsBrief: Compass Announces Inducement Grants Under Nasdaq Listing Rule
US RESEARCH ROUNDUP- Allstate, Autozone, Vertex Pharmaceuticals
U.S. STOCKS ON THE MOVE-Greenland Mines, GameStop, Shopify
U.S. STOCKS ON THE MOVE-Vicor, Thor Industries, Lennar
Brief: Compass Therapeutics Provides Regulatory Update On Tovecimig In Biliary Tract Cancer Following FDA Feedback